Navigation Links
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
Date:11/7/2007

Patients with Painful and Progressive Form of Inflammatory Spinal Arthritis

Receiving Monthly Golimumab Treatment Showed Marked Improvements in

Physical Function

BOSTON, Nov. 7 /PRNewswire/ -- More than half of patients receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis, according to Phase 3 study results presented at the American College of Rheumatology (ACR) annual meeting. At week 14 of the study, 59 percent of patients receiving golimumab 50 mg and 60 percent of patients receiving golimumab 100 mg achieved at least 20 percent improvement in the Assessment in Ankylosing Spondylitis criteria (ASAS 20) compared with 22 percent of patients receiving placebo (P < 0.001). Investigators also reported that study subjects receiving golimumab 50 mg or golimumab 100 mg showed significant, sustained improvements in physical function through six months as measured by the Bath Ankylosing Spondylitis Functional Index (BASFI).

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy.

"The rapid and significant effects of golimumab as demonstrated by these study findings are encouraging for the rheumatology community and for the patients living with this debilitating disease," said Jurgen Braun, MD, lead physician at the Rheumatological Center in Herne, Germany, professor at the Ruhr-Universitat of Bochum, Germany, and lead study inves
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
7. Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
8. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Hospital (MGH) Cancer Center has purchased four radiation therapy treatment ... and one Elekta Synergy® S. The order, which includes ... facility to offer patients a complete cancer treatment solution from ... systems position MGH to take advantage of Volumetric ...
... 2 The Asthma and Allergy Foundation of America (AAFA) ... annual research project ranks the fall,s 100 most challenging cities ... this year are: McAllen, TX (1); Wichita, KS (2); Louisville, ... In addition, according to a recent AAFA survey, fall ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:5/25/2013)... An experienced Chandler dentist has just ... JD Media Surge, LLC. , http://www.ChandlerDentalExcellence.com/Teeth-Whitening.php ... depending on the treatment, can be performed in the ... best method will be chosen for the individual patient. ... A special peroxide-based whitening gel is used along with ...
(Date:5/25/2013)... Actos lawsuit claims pending ... Court, Western District of Louisiana, continue to move forward, ... Management Order issued on May 21st, the Court has ... in the Actos bladder cancer litigation, as well as ... Liability Litigation, MDL No. 2299) , “We continue to ...
(Date:5/25/2013)... 25, 2013 Radius Engineering International ... company in the US and has been building ... over 35 years. M.E. and President, Walton McCarthy, ... NBC Weapon Fundamentals and Shelter Engineering Standards, Sixth ... on shelter engineering. McCarthy is considered the leading ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On May ... many people do not wish to discuss or plan for ... life. FuneralFinancials.com released a Must-Do List to ... 1. Funeral Financials recommends, “Creating a personal fact sheet.” , ... to organize financial information and personal data. It may ...
(Date:5/25/2013)... 2013 On May 25, Voices Against ... and advocacy, comments on a new study by the ... cold atmospheric plasma into brain cancer treatment may help ... a Science Daily article, physicists from the ... physicians demonstrated the “synergistic effect of cold atmospheric plasma ...
Breaking Medicine News(10 mins):Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... take on pilots, health,workplace injuries connected to chronic ... be presented at Preventive Medicine 2008,the American College ... Austin, Texas., Long-Haul Flights May be Hazardous ... acute stress phenomena associated with,frequent take offs and ...
... together to provide dental offices with exposure, to the ... and other Sikka Software products that assist, dentists and their ... performance of their practice. Dental Economics will utilize,Sikka Software,s trending, ... ...
... transaction will be hosted at 11:30 am Eastern ... on ... Inc. ("Meadowbrook") (NYSE: MIG ) and ProCentury,Corporation ("ProCentury") (Nasdaq: ... a transaction valued at,approximately $272.6 million in cash and stock to ...
... Feb. 20 According to Anapol ... http://www.anapolschwartz.com/attorneys/jim_ronca.shtml ), a New England,Journal of ... in the February 21, 2008, print ... Trasylol(R), used in coronary artery bypass ...
... Dana-Farber Cancer Institute have found a previously unknown molecular ... blood vessels when body parts are jeopardized by poor ... understanding of blood vessel formation. In the future, though, ... could be manipulated as a means of treating heart ...
... / ST. PAUL (February 20, 2008) Understanding the ... help in the battle against AIDS, and University of ... direction., Hiroshi Matsuo, Ph.D., and Reuben Harris, Ph.D., co-investigators ... of Biochemistry, Molecular Biology and Biophysics at the University ...
Cached Medicine News:Health News:News Briefs from Preventive Medicine 2008 2Health News:News Briefs from Preventive Medicine 2008 3Health News:Sikka Software and Dental Economics Announce Alliance 2Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 2Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 3Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 4Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 5Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 6Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 7Health News:Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation 2Health News:Another way to grow blood vessels 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: